Vertex Pharmaceuticals (VRTX) reached $470.1 at the closing of the latest trading day, reflecting a -1.17% change compared to ...

Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.

FILSPARI drives IgAN growth, but FSGS approval could unlock a $2 billion market amid rising competition. Read here for more.

The biotech could be on the verge of expanding its lineup and entering a new era of growth.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance ...

Fintel reports that on January 28, 2026, Barclays upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 6.18% Upside As of ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

Investing.com -- The biotechnology sector continues to offer compelling investment opportunities in 2026, with several companies poised for significant growth according to Bank of America analysts.

Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

Both platforms are backed by over 50 peer-reviewed publications representing decades of development. The addressable markets span multiple areas: Alzheimer's disease ($32.8 billion by 2033), ...

Vertex Pharmaceuticals has just seen its price target move from a previously unspecified level to a new, undisclosed figure.